経口タンパク質・ペプチド市場 – 2030年までの世界予測

この調査レポートでは、経口タンパク質・ペプチド市場を、分子（トロフィネチド、セマグルチド、リナクロチド、ボクロスポリン、プレカナチド、カルシトニン、その他の薬物）、薬物クラス（グリシンプロリングルタミン酸（GPE）類似体、グルカゴン様ペプチド-1（GLP-1）受容体作動薬、グアニル酸シクラーゼ-C作動薬、カルシニューリン阻害性免疫抑制薬、カルシトニン遺伝子関連ペプチド（CGRP）受容体拮抗薬、その他の薬物）、治療領域（遺伝性疾患、糖尿病、腎臓病、消化器病、中枢神経系疾患、肥満および過体重、その他の治療領域）、剤形（錠剤、カプセル剤、経口液剤）、エンドユーザー（在宅ケア環境、長期ケア施設、病院および専門クリニック）、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。本レポートは、経口タンパク質・ペプチド市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの包括的な分析を実施し、経口タンパク質・ペプチド市場に関連する事業概要、製品、ソリューション、戦略、提携、パートナーシップ、契約、新製品発売、買収、および最近の動向に関する洞察を提供しています。

The global market for oral proteins and peptides is projected to reach USD 24.00 billion by 2030 from USD 8.85 billion in 2025, at a CAGR of 22.1% during the forecast period from 2025 to 2030.

経口タンパク質・ペプチドの世界市場は、2025年から2030年の予測期間中に22.1%のCAGRで成長し、2025年の88億5,000万米ドルから2030年には240億米ドルに達すると予測されています。

The increase in demand for oral peptides, particularly for the treatment of chronic diseases such as diabetes and central nervous system (CNS) disorders, is a major driver of growth in this market. Additionally, rising investments in research and development by key players are leading to the creation and launch of innovative oral peptides. Continuous advancements in drug delivery technologies are also contributing to market expansion.

経口ペプチド、特に糖尿病や中枢神経系（CNS）疾患などの慢性疾患治療における需要の増加は、この市場の成長を牽引する大きな要因となっています。さらに、主要企業による研究開発への投資の増加は、革新的な経口ペプチドの創出と上市につながっています。薬物送達技術の継続的な進歩も、市場拡大に貢献しています。

However, the market faces challenges, including high development costs and obstacles related to formulation and stability, which hinder growth.

“The semaglutide molecule segment accounted for the largest share of the market, by molecule, in 2024.”

In 2024, the semaglutide segment held the largest share of the global oral proteins and peptides market. Semaglutide is an analog of glucagon-like peptide-1 (GLP-1), a hormone that plays a key role in regulating blood sugar levels and appetite. It is used to manage type 2 diabetes and obesity. Semaglutide functions by enhancing insulin secretion in response to elevated blood glucose levels, reducing glucagon release (which normally raises blood sugar), and promoting a feeling of fullness after eating, thereby helping to reduce food intake.

Oral semaglutide, marketed as RYBELSUS, is the first oral GLP-1 receptor agonist approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely utilized and recommended for managing type 2 diabetes.

“The US will continue to dominate the oral proteins and peptides market during the forecast period.”

The US is the largest biopharmaceutical market in the world and a leader in biopharmaceutical research and investments. This growth is driven by several factors, including the increasing patient population suffering from infectious diseases, the rising importance of biopharmaceuticals, and the need for safe, high-quality products in the healthcare sector. There has been a significant increase in investments and funding for biomedical research from government agencies as well as pharmaceutical and biotechnology companies.

Furthermore, the early adoption of emerging technologies and alternative therapies and the widespread availability of oral proteins and peptides in the region support market expansion. The strong presence of several key market players, including Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), and Pfizer Inc. (US), is another crucial factor contributing to this growth.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and Middle East & Africa (5%)

List of Key Companies Profiled in the Report:

Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc. (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc. (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio Ltd. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)

Research Coverage:

This research report categorizes the oral proteins and peptides market by molecule (trofinetide, semaglutide, linaclotide, voclosporin, plecanatide, calcitonin, and other drugs), drug class (analog of glycine-proline-glutamate (GPE), glucagon-like peptide-1 (GLP-1) receptor agonists, guanylate cyclase-C agonists, calcineurin-inhibitor immunosuppressants, calcitonin gene-related peptide (CGRP) receptor antagonists, and other drugs), therapeutic area (genetic disorders, diabetes, nephrology, gastroenterology, CNS disorders, obesity & overweight, and other therapeutic areas), formulation (tablets, capsules, and oral solutions), end user (home care settings, long-term care facilities, and hospitals & specialty clinics), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overview, products, solutions, strategies, collaborations, partnerships, agreements, new launches, acquisitions, and recent developments associated with the oral proteins and peptides market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, gastroenterology diseases, and kidney diseases; advancements in drug delivery technologies; patient preference and compliance for oral route of drug administration; and increasing adoption of inorganic growth strategies such as collaborations and agreements), restraints (high cost associated with drug development, contraindication of oral proteins and peptides, and stringent regulatory approval process), opportunities (robust clinical trial pipeline for oral proteins and peptides and growing demand for non-invasive and patient-friendly treatment options), and Challenges (hurdles in formulation and stability and availability of alternative therapies) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the oral proteins and peptides market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.

Table of Contents

1               INTRODUCTION              32

1.1           STUDY OBJECTIVES       32

1.2           MARKET DEFINITION   32

1.3           MARKET SCOPE                33

1.3.1        MARKETS AND REGIONS COVERED         33

1.3.2        INCLUSIONS & EXCLUSIONS       34

1.3.3        YEARS CONSIDERED      34

1.3.4        CURRENCY CONSIDERED            35

1.4           STAKEHOLDERS               35

1.5           SUMMARY OF CHANGES               35

2               RESEARCH METHODOLOGY       36

2.1           RESEARCH DATA              36

2.1.1        RESEARCH DESIGN         36

2.1.2        SECONDARY DATA          37

2.1.3        PRIMARY DATA 37

2.2           MARKET SIZE ESTIMATION         39

2.2.1        INSIGHTS FROM PRIMARIES       41

2.2.2        MARKET SIZE ASSESSMENT AT SEGMENT LEVEL                 41

2.3           MARKET GROWTH FORECAST   42

2.4           MARKET BREAKDOWN & DATA TRIANGULATION                 44

2.5           STUDY ASSUMPTIONS  45

2.6           RESEARCH LIMITATIONS             45

2.7           RISK ANALYSIS  45

3               EXECUTIVE SUMMARY  46

4               PREMIUM INSIGHTS       50

4.1           ORAL PROTEINS & PEPTIDES MARKET OVERVIEW                 50

4.2           NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2024)                 51

4.3           ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2024            51

4.4           ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2025 VS. 2030          52

4.5           ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         52

5               MARKET OVERVIEW       53

5.1           INTRODUCTION              53

5.2           MARKET DYNAMICS       53

5.2.1        DRIVERS               54

5.2.1.1    Increasing burden of chronic diseases               54

5.2.1.2    Advancements in drug delivery technologies   55

5.2.1.3    Higher patient compliance and preference for oral route                 55

5.2.1.4    Expanding therapeutic applications of oral proteins & peptides                 55

5.2.2        RESTRAINTS      56

5.2.2.1    High cost of drug development          56

5.2.2.2    Contraindication of oral proteins & peptides   56

5.2.2.3    Stringent regulatory approval process               56

5.2.3        OPPORTUNITIES              57

5.2.3.1    Robust clinical trial pipeline for oral proteins & peptides                 57

5.2.3.2    Growing demand for personalized medicine   57

5.2.4        CHALLENGES    58

5.2.4.1    Hurdles in formulation and stability 58

5.2.4.2    Availability of alternative therapies   58

5.3           ECOSYSTEM ANALYSIS  59

5.3.1        ROLE OF RAW MATERIAL VENDORS       60

5.3.2        ROLE OF PRODUCT PROVIDERS               60

5.3.3        ROLE OF END USERS      60

5.3.4        ROLE OF REGULATORY AUTHORITIES  61

5.4           VALUE CHAIN ANALYSIS               61

5.5           SUPPLY CHAIN ANALYSIS             63

5.6           PORTER’S FIVE FORCES ANALYSIS           64

5.6.1        THREAT OF NEW ENTRANTS      65

5.6.2        THREAT OF SUBSTITUTES          65

5.6.3        BARGAINING POWER OF SUPPLIERS       66

5.6.4        BARGAINING POWER OF BUYERS             66

5.6.5        INTENSITY OF COMPETITIVE RIVALRY 66

5.7           KEY STAKEHOLDERS & BUYING CRITERIA            66

5.7.1        KEY STAKEHOLDERS     66

5.7.2        BUYING CRITERIA           67

5.8           PRICING ANALYSIS          69

5.8.1        AVERAGE SELLING PRICE, BY KEY PLAYER           69

5.8.2        AVERAGE SELLING PRICE, BY COUNTRY & REGION                 70

5.9           REGULATORY LANDSCAPE         71

5.9.1        REGULATORY SCENARIO             71

5.9.2        REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             72

5.10         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       75

5.11         TECHNOLOGY ANALYSIS             75

5.11.1      KEY TECHNOLOGIES     75

5.11.1.1  Transient permeation enhancers       75

5.11.1.2  Gastrointestinal permeation enhancement technology  75

5.11.1.3  Oral sCT (OSTORA) technology      76

5.11.2      COMPLEMENTARY TECHNOLOGIES       76

5.11.2.1  Peptelligence         76

5.11.2.2  ThioMatrix             76

5.11.2.3  Transferrin-based recombinant fusion proteins              77

5.11.3      ADJACENT TECHNOLOGIES       77

5.11.3.1  Oramed and Orasome         77

5.11.3.2  Q-sphera                77

5.11.3.3  Nanoinclusion       77

5.11.3.4  Oleotec and Soctec               78

5.12         PIPELINE ANALYSIS        78

5.13         PATENT ANALYSIS          79

5.13.1      METHODOLOGY              79

5.13.2      PATENTS APPLIED AND GRANTED, 2014–2025    79

5.14         REIMBURSEMENT SCENARIO     82

5.15         KEY CONFERENCES & EVENTS, 2025–2026              82

5.16         INVESTMENT & FUNDING SCENARIO     83

5.17         IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET               85

5.18         IMPACT OF 2025 US TARIFFS—ORAL PROTEINS & PEPTIDES MARKET         86

5.18.1      INTRODUCTION              86

5.18.2      KEY TARIFF RATES          86

5.18.3      PRICE IMPACT ANALYSIS             87

5.18.4      IMPACT ON COUNTRIES/REGIONS         87

5.18.4.1  US           87

5.18.4.2  Europe   87

5.18.4.3  Asia Pacific            88

5.18.5      IMPACT ON MANUFACTURING INDUSTRIES      88

5.18.6      RECOMMENDATIONS FOR MANUFACTURERS   88

6               ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE                 90

6.1           INTRODUCTION              91

6.2           SEMAGLUTIDE 91

6.2.1        INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH          91

6.3           CALCITONIN     94

6.3.1        NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION    94

6.4           LINACLOTIDE   97

6.4.1        RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH        97

6.5           TROFINETIDE   99

6.5.1        FDA APPROVAL TO DRIVE MARKET        99

6.6           VOCLOSPORIN 102

6.6.1        INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION          102

6.7           PLECANATIDE  104

6.7.1        INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH             104

6.8           OTHER MOLECULES      107

7               ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS                 110

7.1           INTRODUCTION              111

7.2           GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS                 111

7.2.1        INCREASING ADOPTION TO SUPPORT GROWTH                 111

7.3           CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS 114

7.3.1        INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION         114

7.4           GUANYLATE CYCLASE-C AGONISTS       117

7.4.1        RISING PREVALENCE OF IBS AND CIC TO DRIVE MARKET               117

7.5           GLYCINE-PROLINE-GLUTAMATE             119

7.5.1        FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH        119

7.6           CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS                 122

7.6.1        INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH      122

7.7           OTHER DRUG CLASSES 124

8               ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION 127

8.1           INTRODUCTION              128

8.2           TABLETS              128

8.2.1        HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH        128

8.3           CAPSULES           131

8.3.1        RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET                 131

8.4           ORAL SOLUTIONS           134

8.4.1        GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH                 134

9               ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA      137

9.1           INTRODUCTION              138

9.2           DIABETES           138

9.2.1        HIGH EFFICACY TO SUPPORT END-USER ADOPTION                 138

9.3           CNS DISORDERS               142

9.3.1        GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET             142

9.4           GASTROENTEROLOGY 145

9.4.1        RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH  145

9.5           GENETIC DISORDERS    148

9.5.1        GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH        148

9.6           NEPHROLOGY  151

9.6.1        RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET 151

9.7           OBESITY & OVERWEIGHT            153

9.7.1        RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH             153

9.8           OTHER THERAPEUTIC AREAS    156

10            ORAL PROTEINS & PEPTIDES MARKET, BY END USER                 159

10.1         INTRODUCTION              160

10.2         HOME CARE SETTINGS 160

10.2.1      RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH             160

10.3         LONG-TERM CARE FACILITIES  163

10.3.1      RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH       163

10.4         HOSPITALS & SPECIALTY CLINICS           166

10.4.1      ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO DRIVE MARKET            166

11            ORAL PROTEINS & PEPTIDES MARKET, BY REGION                 170

11.1         INTRODUCTION              171

11.2         NORTH AMERICA             171

11.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 172

11.2.2      US           176

11.2.2.1  US to hold large shares in North American and global markets                 176

11.2.3      CANADA               178

11.2.3.1  Increasing prevalence of obesity and heart failure to

support market growth        178

11.3         EUROPE               180

11.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      181

11.3.2      GERMANY           185

11.3.2.1  Germany to hold largest share of European market        185

11.3.3      UK          188

11.3.3.1  Strong focus on advancement of life sciences to support market growth    188

11.3.4      FRANCE                190

11.3.4.1  Growing prevalence of diabetes and government initiatives to boost market growth             190

11.3.5      ITALY    193

11.3.5.1  Presence of major pharmaceutical and biotechnology companies to drive market      193

11.3.6      SPAIN    195

11.3.6.1  Initiatives associated with GLP-1 drugs to drive market                 195

11.3.7      NETHERLANDS 198

11.3.7.1  Rising awareness and focus on pharmaceutical R&D to support market growth       198

11.3.8      REST OF EUROPE             200

11.4         ASIA PACIFIC     202

11.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 203

11.4.2      CHINA  207

11.4.2.1  Increasing R&D expenditure to drive market  207

11.4.3      JAPAN   209

11.4.3.1  Increasing prevalence of diabetes to drive market           209

11.4.4      INDIA    212

11.4.4.1  Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth      212

11.4.5      AUSTRALIA         214

11.4.5.1  Rising access to GLP-1 drugs and government support to drive market    214

11.4.6      SOUTH KOREA  217

11.4.6.1  Growing focus on development of innovative treatment solutions to propel market growth      217

11.4.7      REST OF ASIA PACIFIC   219

11.5         LATIN AMERICA                222

11.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 222

11.5.2      BRAZIL 225

11.5.2.1  Brazil to hold largest market share in Latin America      225

11.5.3      MEXICO                228

11.5.3.1  Growing diabetes and obesity cases to drive market       228

11.5.4      REST OF LATIN AMERICA             230

11.6         MIDDLE EAST   233

11.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST                 233

11.6.2      GCC COUNTRIES              236

11.6.2.1  Saudi Arabia          239

11.6.2.1.1                Growing availability of GLP-1 drugs to support market growth    239

11.6.2.2  UAE        241

11.6.2.2.1                Regulatory approvals for GLP-1 drugs to propel market                 241

11.6.2.3  Rest of GCC countries         244

11.6.3      REST OF MIDDLE EAST 246

11.7         AFRICA 248

11.7.1      LARGE AND GROWING PATIENT POPULATION AND FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET                 248

11.7.2      MACROECONOMIC OUTLOOK FOR AFRICA        248

12            COMPETITIVE LANDSCAPE         252

12.1         OVERVIEW          252

12.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            252

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET  252

12.3         REVENUE ANALYSIS, 2022–2024  253

12.4         MARKET SHARE ANALYSIS, 2024                 254

12.5         COMPANY EVALUATION MATRIX             256

12.5.1      COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 256

12.5.1.1  Stars        256

12.5.1.2  Emerging leaders 256

12.5.1.3  Pervasive players  257

12.5.1.4  Participants           257

12.5.2      COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2024     258

12.5.2.1  Stars        258

12.5.2.2  Emerging leaders 258

12.5.2.3  Pervasive players  258

12.5.2.4  Participants           258

12.5.3      COMPANY FOOTPRINT: KEY PLAYERS, 2024         260

12.5.3.1  Company footprint               260

12.5.3.2  Region footprint   262

12.5.3.3  Molecule footprint                263

12.5.3.4  Formulation footprint          264

12.5.3.5  Therapeutic area footprint  264

12.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        266

12.6.1      PROGRESSIVE COMPANIES         266

12.6.2      RESPONSIVE COMPANIES            266

12.6.3      DYNAMIC COMPANIES  266

12.6.4      STARTING BLOCKS         266

12.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 268

12.6.5.1  Detailed list of key startups/SMEs    268

12.6.5.2  Competitive benchmarking of key startups/SMEs          269

12.7         VALUATION & FINANCIAL METRICS       270

12.7.1      FINANCIAL METRICS      270

12.7.2      COMPANY VALUATION 270

12.8         BRAND/PRODUCT COMPARISON             271

12.9         COMPETITIVE SCENARIO             271

12.9.1      PRODUCT APPROVALS 271

12.9.2      DEALS  273

12.9.3      EXPANSIONS     274

12.9.4      OTHER DEVELOPMENTS              275

13            COMPANY PROFILES      276

13.1         INTRODUCTION              276

13.2         KEY PLAYERS     276

13.2.1      NOVO NORDISK A/S       276

13.2.1.1  Business overview 276

13.2.1.2  Products offered   277

13.2.1.3  Recent developments           278

13.2.1.3.1                Product launches & approvals            278

13.2.1.3.2                Deals      278

13.2.1.3.3                Expansions             279

13.2.1.3.4                Other developments             280

13.2.1.4  MnM view              280

13.2.1.4.1                Right to win           280

13.2.1.4.2                Strategic choices   280

13.2.1.4.3                Weaknesses & competitive threats     280

13.2.2      ABBVIE INC.       281

13.2.2.1  Business overview 281

13.2.2.2  Products offered   282

13.2.2.3  Recent developments           283

13.2.2.3.1                Product approvals 283

13.2.2.3.2                Deals      283

13.2.2.4  MnM view              284

13.2.2.4.1                Right to win           284

13.2.2.4.2                Strategic choices   284

13.2.2.4.3                Weaknesses & competitive threats     284

13.2.3      PFIZER INC.        285

13.2.3.1  Business overview 285

13.2.3.2  Product pipeline   286

13.2.3.3  Recent developments           287

13.2.3.3.1                Product approvals 287

13.2.3.3.2                Deals      287

13.2.3.3.3                Other developments             287

13.2.3.4  MnM view              288

13.2.3.4.1                Right to win           288

13.2.3.4.2                Strategic choices   288

13.2.3.4.3                Weaknesses & competitive threats     288

13.2.4      BAUSCH HEALTH COMPANIES INC.         289

13.2.4.1  Business overview 289

13.2.4.2  Products offered   290

13.2.4.3  Recent developments           291

13.2.4.3.1                Product approvals 291

13.2.5      CHIESI FARMACEUTICI S.P.A.     292

13.2.5.1  Business overview 292

13.2.5.2  Products offered   293

13.2.5.3  Recent developments           294

13.2.5.3.1                Deals      294

13.2.6      ACADIA PHARMACEUTICALS INC.            295

13.2.6.1  Business overview 295

13.2.6.2  Products offered   296

13.2.6.3  Recent developments           296

13.2.6.3.1                Product approvals 296

13.2.7      AURINIA PHARMACEUTICALS INC.          297

13.2.7.1  Business overview 297

13.2.7.2  Products offered   298

13.2.7.3  Recent developments           298

13.2.7.3.1                Product approvals 298

13.2.8      MERCK & CO., INC.          300

13.2.8.1  Business overview 300

13.2.8.2  Product pipeline   301

13.2.8.3  Recent developments           302

13.2.8.3.1                Deals      302

13.2.8.3.2                Other developments             302

13.2.9      JOHNSON & JOHNSON SERVICES, INC.   303

13.2.9.1  Business overview 303

13.2.9.2  Product pipeline   304

13.2.9.3  Recent developments           305

13.2.9.3.1                Other developments             305

13.2.10   SWK HOLDINGS                306

13.2.10.1                 Business overview 306

13.2.10.2                 Product pipeline   307

13.2.10.3                 Recent developments           307

13.2.10.3.1             Other developments             307

13.2.11   R-PHARM JSC     308

13.2.11.1                 Business overview 308

13.2.11.2                 Products in pipeline             308

13.2.12   ENTERA BIO LTD.            309

13.2.12.1                 Business overview 309

13.2.12.2                 Product pipeline   309

13.2.12.3                 Recent developments           310

13.2.12.3.1             Deals      310

13.2.12.3.2             Other developments             310

13.2.13   PROXIMA CONCEPTS     311

13.2.13.1                 Business overview 311

13.2.13.2                 Products in pipeline             311

13.3         OTHER PLAYERS              312

13.3.1      ASTRAZENECA PLC         312

13.3.2      REGOR THERAPEUTICS GROUP                 312

13.3.3      TERNS PHARMACEUTICALS, INC.             313

13.3.4      STRUCTURE THERAPEUTICS     313

13.3.5      VIKING THERAPEUTICS                314

13.3.6      PROTAGONIST THERAPEUTICS INC.      314

13.3.7      RANI THERAPEUTICS     315

13.3.8      CARMOT THERAPEUTICS, INC. 315

13.3.9      ZEALAND PHARMA         316

13.3.10   SCIWIND BIOSCIENCES CO., LTD.             316

13.3.11   JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.                 317

14            APPENDIX           318

14.1         DISCUSSION GUIDE        318

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                322

14.3         CUSTOMIZATION OPTIONS        324

14.4         RELATED REPORTS         324

14.5         AUTHOR DETAILS           325

LIST OF TABLES

TABLE 1                ORAL PROTEINS & PEPTIDES MARKET: IMPACT ANALYSIS            54

TABLE 2                ORAL PROTEINS & PEPTIDES MARKET: ROLE OF RAW MATERIAL VENDORS           60

TABLE 3                ORAL PROTEINS & PEPTIDES MARKET: ROLE OF PRODUCT PROVIDERS  60

TABLE 4                ORAL PROTEINS & PEPTIDES MARKET: ROLE OF END USERS         60

TABLE 5                ORAL PROTEINS & PEPTIDES MARKET: ROLE OF REGULATORY AUTHORITIES     61

TABLE 6                ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS           64

TABLE 7                BUYING CRITERIA FOR ORAL PROTEINS & PEPTIDES, BY END USER               68

TABLE 8                AVERAGE SELLING PRICE OF ORAL PROTEIN & PEPTIDE PRODUCTS,

BY KEY PLAYER, 2024 (USD)         69

TABLE 9                AVERAGE SELLING PRICE OF ORAL PROTEIN & PEPTIDE PRODUCTS,

BY COUNTRY AND REGION, 2024 (USD) 70

TABLE 10              REGULATORY SCENARIO FOR ORAL PROTEINS & PEPTIDES MARKET     71

TABLE 11              NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  72

TABLE 12              EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  72

TABLE 13              ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  73

TABLE 14              REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             74

TABLE 15              ORAL PEPTIDES IN CLINICAL PIPELINE (AS OF JANUARY 2025)  78

TABLE 16              PATENTS FILED, 2014–2025           79

TABLE 17              INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024              81

TABLE 18              ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF

CONFERENCES & EVENTS            82

TABLE 19              US ADJUSTED RECIPROCAL TARIFF RATES                 86

TABLE 20              ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)  91

TABLE 21              SEMAGLUTIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 92

TABLE 22              NORTH AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            92

TABLE 23              EUROPE: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     92

TABLE 24              ASIA PACIFIC: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     93

TABLE 25              LATIN AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            93

TABLE 26              MIDDLE EAST: SEMAGLUTIDE MARKET, BY REGION, 2023–2030 (USD MILLION)          93

TABLE 27              GCC COUNTRIES: SEMAGLUTIDE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            94

TABLE 28              CALCITONIN MARKET, BY REGION, 2023–2030 (USD MILLION) 94

TABLE 29              NORTH AMERICA: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     95

TABLE 30              EUROPE: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            95

TABLE 31              ASIA PACIFIC: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     95

TABLE 32              LATIN AMERICA: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     96

TABLE 33              MIDDLE EAST: CALCITONIN MARKET, BY REGION, 2023–2030 (USD MILLION)          96

TABLE 34              GCC COUNTRIES: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     96

TABLE 35              LINACLOTIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 97

TABLE 36              NORTH AMERICA: LINACLOTIDE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            97

TABLE 37              EUROPE: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            98

TABLE 38              ASIA PACIFIC: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     98

TABLE 39              LATIN AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     98

TABLE 40              MIDDLE EAST: LINACLOTIDE MARKET, BY REGION, 2023–2030 (USD MILLION)          99

TABLE 41              GCC COUNTRIES: LINACLOTIDE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            99

TABLE 42              TROFINETIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 100

TABLE 43              NORTH AMERICA: TROFINETIDE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            100

TABLE 44              EUROPE: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            100

TABLE 45              ASIA PACIFIC: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     101

TABLE 46              LATIN AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     101

TABLE 47              MIDDLE EAST: TROFINETIDE MARKET, BY REGION, 2023–2030 (USD MILLION)          101

TABLE 48              GCC COUNTRIES: TROFINETIDE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            102

TABLE 49              VOCLOSPORIN MARKET, BY REGION, 2023–2030 (USD MILLION) 102

TABLE 50              NORTH AMERICA: VOCLOSPORIN MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            103

TABLE 51              EUROPE: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     103

TABLE 52              ASIA PACIFIC: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     103

TABLE 53              LATIN AMERICA: VOCLOSPORIN MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            104

TABLE 54              PLECANATIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 104

TABLE 55              NORTH AMERICA: PLECANATIDE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            105

TABLE 56             EUROPE: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            105

TABLE 57              ASIA PACIFIC: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     105

TABLE 58              LATIN AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     106

TABLE 59              MIDDLE EAST: PLECANATIDE MARKET, BY REGION, 2023–2030 (USD MILLION)          106

TABLE 60              GCC COUNTRIES: PLECANATIDE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)          106

TABLE 61              OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION,

2023–2030 (USD MILLION)            107

TABLE 62              NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               107

TABLE 63              EUROPE: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               108

TABLE 64              ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               108

TABLE 65              LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               109

TABLE 66              MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,

BY REGION, 2023–2030 (USD MILLION)   109

TABLE 67              GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               109

TABLE 68              ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            111

TABLE 69              GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)          112

TABLE 70              NORTH AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            112

TABLE 71              EUROPE: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            112

TABLE 72              ASIA PACIFIC: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            113

TABLE 73              LATIN AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            113

TABLE 74              MIDDLE EAST: GLP-1 RECEPTOR AGONISTS MARKET, BY REGION,

2023–2030 (USD MILLION)            113

TABLE 75              GCC COUNTRIES: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            114

TABLE 76              CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)          114

TABLE 77              NORTH AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            115

TABLE 78              EUROPE: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            115

TABLE 79              ASIA PACIFIC: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            115

TABLE 80              LATIN AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            116

TABLE 81              MIDDLE EAST: CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION,

2023–2030 (USD MILLION)            116

TABLE 82              GCC COUNTRIES: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            116

TABLE 83              GC-C AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)       117

TABLE 84              NORTH AMERICA: GC-C AGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            117

TABLE 85              EUROPE: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     118

TABLE 86              ASIA PACIFIC: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     118

TABLE 87              LATIN AMERICA: GC-C AGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            118

TABLE 88              MIDDLE EAST: GC-C AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)          119

TABLE 89              GCC COUNTRIES: GC-C AGONISTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            119

TABLE 90              GPE MARKET, BY REGION, 2023–2030 (USD MILLION)            120

TABLE 91              NORTH AMERICA: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            120

TABLE 92              EUROPE: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120

TABLE 93              ASIA PACIFIC: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            121

TABLE 94              LATIN AMERICA: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            121

TABLE 95              MIDDLE EAST: GPE MARKET, BY REGION, 2023–2030 (USD MILLION)       121

TABLE 96              GCC COUNTRIES: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            122

TABLE 97              CNI MARKET, BY REGION, 2023–2030 (USD MILLION)            122

TABLE 98              NORTH AMERICA: CNI MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            123

TABLE 99              EUROPE: CNI MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123

TABLE 100            ASIA PACIFIC: CNI MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       123

TABLE 101            OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION,

2023–2030 (USD MILLION)            124

TABLE 102            NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               125

TABLE 103            EUROPE: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               125

TABLE 104            ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               125

TABLE 105            LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               126

TABLE 106            MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,

BY REGION, 2023–2030 (USD MILLION)   126

TABLE 107            GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               126

TABLE 108            ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            128

TABLE 109            ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION,

2023–2030 (USD MILLION)            129

TABLE 110            NORTH AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 129

TABLE 111            EUROPE: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            129

TABLE 112            ASIA PACIFIC: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            130

TABLE 113            LATIN AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 130

TABLE 114            MIDDLE EAST: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION,

2023–2030 (USD MILLION)            130

TABLE 115            GCC COUNTRIES: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 131

TABLE 116            ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION,

2023–2030 (USD MILLION)            131

TABLE 117            NORTH AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 132

TABLE 118            EUROPE: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            132

TABLE 119            ASIA PACIFIC: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            132

TABLE 120            LATIN AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 133

TABLE 121            MIDDLE EAST: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION,

2023–2030 (USD MILLION)            133

TABLE 122            GCC COUNTRIES: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 133

TABLE 123            ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION,

2023–2030 (USD MILLION)            134

TABLE 124            NORTH AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 134

TABLE 125            EUROPE: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            135

TABLE 126            ASIA PACIFIC: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 135

TABLE 127            LATIN AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 136

TABLE 128            MIDDLE EAST: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION,

2023–2030 (USD MILLION)            136

TABLE 129            GCC COUNTRIES: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 136

TABLE 130            ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            138

TABLE 131            ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION,

2023–2030 (USD MILLION)            139

TABLE 132            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,

BY COUNTRY, 2023–2030 (USD MILLION)               139

TABLE 133            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION)                 140

TABLE 134            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION)            140

TABLE 135            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,

BY COUNTRY, 2023–2030 (USD MILLION)               141

TABLE 136            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION, 2023–2030 (USD MILLION)                 141

TABLE 137            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,

BY COUNTRY, 2023–2030 (USD MILLION)               141

TABLE 138            ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION,

2023–2030 (USD MILLION)            142

TABLE 139            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               143

TABLE 140            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               143

TABLE 141            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               143

TABLE 142            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               144

TABLE 143            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,

BY REGION, 2023–2030 (USD MILLION)   144

TABLE 144            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               144

TABLE 145            ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2023–2030 (USD MILLION)                 145

TABLE 146            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 146

TABLE 147            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               146

TABLE 148            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               146

TABLE 149            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 147

TABLE 150            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2023–2030 (USD MILLION) 147

TABLE 151            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 147

TABLE 152            ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)                 148

TABLE 153            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 149

TABLE 154            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               149

TABLE 155            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               149

TABLE 156            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 150

TABLE 157            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)            150

TABLE 158            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 150

TABLE 159            ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY REGION,

2023–2030 (USD MILLION)            151

TABLE 160            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               152

TABLE 161            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 152

TABLE 162            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               152

TABLE 163            ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2023–2030 (USD MILLION)            153

TABLE 164            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR

OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION)            154

TABLE 165            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT,

BY COUNTRY, 2023–2030 (USD MILLION)               154

TABLE 166            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION)       154

TABLE 167            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION)       155

TABLE 168            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2023–2030 (USD MILLION) 155

TABLE 169            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION)       155

TABLE 170            ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS,

BY REGION, 2023–2030 (USD MILLION)   156

TABLE 171            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)            157

TABLE 172            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 157

TABLE 173            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)            157

TABLE 174            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)            158

TABLE 175            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)       158

TABLE 176            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)            158

TABLE 177            ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)                160

TABLE 178            ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2030 (USD MILLION)                 161

TABLE 179            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 161

TABLE 180            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2023–2030 (USD MILLION)               161

TABLE 181            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 162

TABLE 182            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 162

TABLE 183            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2030 (USD MILLION) 162

TABLE 184            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 163

TABLE 185            ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)            164

TABLE 186            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)            164

TABLE 187            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 164

TABLE 188            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)            165

TABLE 189            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)            165

TABLE 190            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)       165

TABLE 191            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)            166

TABLE 192            ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS,

BY REGION, 2023–2030 (USD MILLION)   167

TABLE 193            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)            167

TABLE 194            EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 167

TABLE 195            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)            168

TABLE 196            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)            168

TABLE 197            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023–2030 (USD MILLION)            168

TABLE 198            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)            169

TABLE 199            ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)          171

TABLE 200            NORTH AMERICA: KEY MACROINDICATORS                 172

TABLE 201            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            173

TABLE 202            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            174

TABLE 203            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            174

TABLE 204            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 175

TABLE 205            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)                 175

TABLE 206            NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            175

TABLE 207            US: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            176

TABLE 208            US: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            176

TABLE 209            US: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            177

TABLE 210            US: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            177

TABLE 211            US: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            177

TABLE 212          CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            178

TABLE 213          CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            179

TABLE 214          CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            179

TABLE 215          CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            180

TABLE 216          CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            180

TABLE 217            EUROPE: KEY MACROINDICATORS          181

TABLE 218            EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            183

TABLE 219            EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            183

TABLE 220            EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            184

TABLE 221            EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            184

TABLE 222            EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            185

TABLE 223            EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            185

TABLE 224            GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            186

TABLE 225            GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            186

TABLE 226            GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            187

TABLE 227            GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)          187

TABLE 228            GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            187

TABLE 229            UK: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            188

TABLE 230            UK: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            189

TABLE 231            UK: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            189

TABLE 232            UK: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            190

TABLE 233            UK: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            190

TABLE 234            FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            191

TABLE 235            FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            191

TABLE 236            FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            192

TABLE 237            FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            192

TABLE 238            FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            192

TABLE 239            ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            193

TABLE 240            ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            194

TABLE 241            ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)          194

TABLE 242            ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            195

TABLE 243            ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            195

TABLE 244            SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            196

TABLE 245            SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            196

TABLE 246            SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            197

TABLE 247            SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            197

TABLE 248            SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)          197

TABLE 249            NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            198

TABLE 250            NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            198

TABLE 251            NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 199

TABLE 252            NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            199

TABLE 253            NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            199

TABLE 254            REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            200

TABLE 255            REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            201

TABLE 256            REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 201

TABLE 257            REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)                 202

TABLE 258            REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            202

TABLE 259            ASIA PACIFIC: KEY MACROINDICATORS                 204

TABLE 260            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            204

TABLE 261            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            205

TABLE 262            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            205

TABLE 263            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 206

TABLE 264            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            206

TABLE 265            ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            206

TABLE 266            CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            207

TABLE 267            CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            208

TABLE 268            CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            208

TABLE 269            CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            209

TABLE 270            CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            209

TABLE 271            JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            210

TABLE 272            JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            210

TABLE 273            JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            211

TABLE 274            JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            211

TABLE 275            JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            211

TABLE 276            INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            212

TABLE 277            INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            213

TABLE 278            INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            213

TABLE 279            INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            214

TABLE 280            INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            214

TABLE 281            AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            215

TABLE 282            AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            215

TABLE 283            AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            216

TABLE 284            AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            216

TABLE 285            AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            216

TABLE 286            SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            217

TABLE 287            SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            218

TABLE 288            SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 218

TABLE 289            SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            219

TABLE 290            SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            219

TABLE 291            REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)                 220

TABLE 292            REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)                 220

TABLE 293            REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            221

TABLE 294            REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)            221

TABLE 295            REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET,

BY END USER, 2023–2030 (USD MILLION)               221

TABLE 296            LATIN AMERICA: KEY MACROINDICATORS                 222

TABLE 297            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)          223

TABLE 298            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            223

TABLE 299            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            224

TABLE 300            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 224

TABLE 301            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            225

TABLE 302            LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)          225

TABLE 303            BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            226

TABLE 304            BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            226

TABLE 305            BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            227

TABLE 306            BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            227

TABLE 307            BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            227

TABLE 308            MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            228

TABLE 309            MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            229

TABLE 310            MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            229

TABLE 311            MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            230

TABLE 312            MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            230

TABLE 313            REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)                 231

TABLE 314            REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)                 231

TABLE 315            REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            232

TABLE 316            REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET,

BY FORMULATION, 2023–2030 (USD MILLION)    232

TABLE 317            REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET,

BY END USER, 2023–2030 (USD MILLION)               232

TABLE 318            MIDDLE EAST: KEY MACROINDICATORS                 233

TABLE 319            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY REGION,

2023–2030 (USD MILLION)            234

TABLE 320            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            234

TABLE 321            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            235

TABLE 322            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 235

TABLE 323            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            236

TABLE 324            MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            236

TABLE 325            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            236

TABLE 326            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            237

TABLE 327            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            237

TABLE 328            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 238

TABLE 329            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            238

TABLE 330            GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            238

TABLE 331            SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            239

TABLE 332            SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            240

TABLE 333            SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 240

TABLE 334            SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            241

TABLE 335            SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            241

TABLE 336            UAE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            242

TABLE 337            UAE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            242

TABLE 338            UAE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)          243

TABLE 339            UAE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            243

TABLE 340            UAE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            243

TABLE 341            REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)                 244

TABLE 342            REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)                 244

TABLE 343            REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET,

BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)          245

TABLE 344            REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET,

BY FORMULATION, 2023–2030 (USD MILLION)    245

TABLE 345            REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)                 245

TABLE 346            REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)                 246

TABLE 347            REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)                 246

TABLE 348            REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            247

TABLE 349            REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)            247

TABLE 350            REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET,

BY END USER, 2023–2030 (USD MILLION)               247

TABLE 351            AFRICA: KEY MACROINDICATORS            249

TABLE 352            AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)            249

TABLE 353            AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,

2023–2030 (USD MILLION)            250

TABLE 354            AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            250

TABLE 355            AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,

2023–2030 (USD MILLION)            251

TABLE 356            AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2023–2030 (USD MILLION)            251

TABLE 357            OVERVIEW OF STRATEGIES DEPLOYED BY KEY ORAL PROTEIN &

PEPTIDE MANUFACTURERS       252

TABLE 358            ORAL PROTEINS & PEPTIDES MARKET: DEGREE OF COMPETITION           255

TABLE 359            ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (KEY PLAYERS)       262

TABLE 360            ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE) 262

TABLE 361            ORAL PROTEINS & PEPTIDES MARKET: MOLECULE FOOTPRINT (KEY PLAYERS)               263

TABLE 362            ORAL PROTEINS & PEPTIDES MARKET: FORMULATION FOOTPRINT (KEY PLAYERS)      264

TABLE 363            ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA

FOOTPRINT (KEY PLAYERS)       264

TABLE 364            ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)     265

TABLE 365            ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF KEY STARTUPS/SMES             268

TABLE 366            ORAL PROTEINS & PEPTIDES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES                 269

TABLE 367            ORAL PROTEINS & PEPTIDES MARKET: PRODUCT APPROVALS,

JANUARY 2021–JANUARY 2025     271

TABLE 368            ORAL PROTEINS & PEPTIDES MARKET: DEALS, JANUARY 2021–JANUARY 2025     273

TABLE 369            ORAL PROTEINS & PEPTIDES MARKET: EXPANSIONS,

JANUARY 2021– JANUARY 2025    274

TABLE 370            ORAL PROTEINS & PEPTIDES MARKET: OTHER DEVELOPMENTS,

JANUARY 2021– JANUARY 2025    275

TABLE 371            NOVO NORDISK A/S: COMPANY OVERVIEW                 276

TABLE 372            NOVO NORDISK A/S: PRODUCTS OFFERED                 277

TABLE 373            NOVO NORDISK A/S: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–MARCH 2025         278

TABLE 374            NOVO NORDISK A/S: DEALS, JANUARY 2021–MARCH 2025       278

TABLE 375            NOVO NORDISK: EXPANSIONS, JANUARY 2021–MARCH 2025       279

TABLE 376            NOVO NORDISK: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025         280

TABLE 377            ABBVIE INC.: COMPANY OVERVIEW        281

TABLE 378            ABBVIE INC.: PRODUCTS OFFERED         282

TABLE 379            ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025         283

TABLE 380            ABBVIE INC.: DEALS, JANUARY 2021–JANUARY 2025        283

TABLE 381            PFIZER INC.: COMPANY OVERVIEW         285

TABLE 382            PFIZER INC.: PRODUCT PIPELINE             286

TABLE 383            PFIZER INC.: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025             287

TABLE 384            PFIZER INC.: DEALS, JANUARY 2021–MARCH 2025                 287

TABLE 385            PFIZER INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025             287

TABLE 386            BAUSCH HEALTH COMPANIES: COMPANY OVERVIEW          289

TABLE 387            BAUSCH HEALTH COMPANIES: PRODUCTS OFFERED             290

TABLE 388            BAUSCH HEALTH COMPANIES: PRODUCT APPROVALS,

JANUARY 2021–JANUARY 2025     291

TABLE 389            CHIESI FARMACEUTICI S.P.A.: COMPANY OVERVIEW          292

TABLE 390            CHIESI FARMACEUTICI S.P.A.: PRODUCTS OFFERED             293

TABLE 391            CHIESI FARMACEUTICI S.P.A.: DEALS, JANUARY 2021–JANUARY 2025         294

TABLE 392            ACADIA PHARMACEUTICALS INC.: COMPANY OVERVIEW          295

TABLE 393            ACADIA PHARMACEUTICALS INC.: PRODUCTS OFFERED             296

TABLE 394            ACADIA PHARMACEUTICALS INC.: PRODUCT APPROVALS,

JANUARY 2021–JANUARY 2025     296

TABLE 395            AURINIA PHARMACEUTICALS INC.: COMPANY OVERVIEW          297

TABLE 396            AURINIA PHARMACEUTICALS INC.: PRODUCTS OFFERED             298

TABLE 397            AURINIA PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025           298

TABLE 398            MERCK & CO., INC.: COMPANY OVERVIEW                 300

TABLE 399            MERCK & CO., INC.: PRODUCT PIPELINE                 301

TABLE 400            MERCK & CO., INC.: DEALS, JANUARY 2021–JANUARY 2025    302

TABLE 401            MERCK & CO., INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025     302

TABLE 402            JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW   303

TABLE 403            JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PIPELINE       304

TABLE 404            JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS,

JANUARY 2021–MARCH 2025       305

TABLE 405            SWK HOLDINGS: COMPANY OVERVIEW 306

TABLE 406            SWK HOLDINGS: PRODUCT PIPELINE    307

TABLE 407            SWK HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025     307

TABLE 408            R-PHARM JSC: COMPANY OVERVIEW      308

TABLE 409            R-PHARM JSC: PRODUCTS IN PIPELINE 308

TABLE 410            ENTERA BIO: COMPANY OVERVIEW       309

TABLE 411            ENTERA BIO: PRODUCT PIPELINE           309

TABLE 412            ENTERA BIO: DEALS, JANUARY 2021–JANUARY 2025        310

TABLE 413            ENTERA BIO: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025     310

TABLE 414            PROXIMA CONCEPTS: COMPANY OVERVIEW                 311

TABLE 415            PROXIMA CONCEPTS: PRODUCTS IN PIPELINE                 311

LIST OF FIGURES

FIGURE 1              BREAKDOWN OF PRIMARIES: SUPPLY AND DEMAND-SIDE PARTICIPANTS  38

FIGURE 2              MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024  39

FIGURE 3              MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2024           40

FIGURE 4              MARKET VALIDATION FROM PRIMARY EXPERTS              41

FIGURE 5              MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH         41

FIGURE 6              CAGR PROJECTIONS: ORAL PROTEINS & PEPTIDES MARKET, 2025–2030    43

FIGURE 7              IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORAL PROTEINS & PEPTIDES MARKET         43

FIGURE 8              DATA TRIANGULATION METHODOLOGY                 44

FIGURE 9              ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,

2025 VS. 2030 (USD MILLION)      46

FIGURE 10            ORAL PROTEINS & PEPTIDES MARKET SHARE, BY DRUG CLASS,

2025 VS. 2030 (USD MILLION)      47

FIGURE 11            ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA,

2025 VS. 2030 (USD MILLION)    47

FIGURE 12            ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION,

2025 VS. 2030 (USD MILLION)      48

FIGURE 13            ORAL PROTEINS & PEPTIDES MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      48

FIGURE 14            GEOGRAPHICAL SNAPSHOT OF ORAL PROTEINS & PEPTIDES MARKET               49

FIGURE 15            INCREASING APPROVALS OF ORAL PROTEIN & PEPTIDE DRUGS TO DRIVE MARKET GROWTH  50

FIGURE 16            TABLETS ACCOUNTED FOR LARGEST SHARE OF

NORTH AMERICAN MARKET IN 2024       51

FIGURE 17            DIABETES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024   51

FIGURE 18            HOME CARE SETTINGS TO DOMINATE MARKET TILL 2030              52

FIGURE 19            UK TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD         52

FIGURE 20           ORAL PROTEINS & PEPTIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES         53

FIGURE 21            ORAL PROTEINS & PEPTIDES MARKET: ECOSYSTEM ANALYSIS  59

FIGURE 22            ORAL PROTEINS & PEPTIDES MARKET: VALUE CHAIN ANALYSIS              62

FIGURE 23            ORAL PROTEINS & PEPTIDES MARKET: SUPPLY CHAIN ANALYSIS              64

FIGURE 24            ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS           65

FIGURE 25            INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF

ORAL PROTEINS & PEPTIDES     66

FIGURE 26            KEY BUYING CRITERIA FOR END USERS                 67

FIGURE 27            TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES           75

FIGURE 28            PATENT ANALYSIS OF ORAL PROTEINS & PEPTIDE MARKET, JANUARY 2014–JANUARY 2025               80

FIGURE 29            ORAL PROTEINS & PEPTIDES MARKET: INVESTMENT & FUNDING SCENARIO     83

FIGURE 30            NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT       173

FIGURE 31            EUROPE: ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT          182

FIGURE 32            REVENUE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET, 2022–2024 (USD MILLION)                 254

FIGURE 33            MARKET SHARE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS &

PEPTIDES (2024)                255

FIGURE 34            ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       257

FIGURE 35            ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX

(PLAYERS WITH PRODUCTS IN PIPELINE), 2024 259

FIGURE 36            ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (KEY PLAYERS) 260

FIGURE 37            ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT

(PLAYERS WITH PRODUCTS IN PIPELINE)            261

FIGURE 38            ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024                 267

FIGURE 39            EV/EBITDA OF KEY VENDORS   270

FIGURE 40            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY VENDORS            270

FIGURE 41            ORAL PROTEINS & PEPTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     271

FIGURE 42            NOVO NORDISK A/S: COMPANY SNAPSHOT (2024)    277

FIGURE 43            ABBVIE INC.: COMPANY SNAPSHOT (2024)                 282

FIGURE 44            PFIZER INC.: COMPANY SNAPSHOT (2024)                 286

FIGURE 45            BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT (2024)             290

FIGURE 46            CHIESI FARMACEUTICI S.P.A.: COMPANY SNAPSHOT (2024)             293

FIGURE 47            ACADIA PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)             295

FIGURE 48            AURINIA PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)             297

FIGURE 49            MERCK & CO., INC.: COMPANY SNAPSHOT (2024)    301

FIGURE 50            JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)      304

FIGURE 51            SWK HOLDINGS: COMPANY SNAPSHOT (2024)                 306

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧